Evidence map›Paper›PMID 28168172›Full record

ArticleClinical and experimental vaccine research2017

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly.

Yu Bin Seo, Won Suk Choi, Jacob Lee, Joon Young Song, Hee Jin Cheong, Woo Joo Kim

Open access · diamondAbstract read
In one paragraph

Article in Clinical and experimental vaccine research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yu Bin SeoDivision of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.ORCID 0000-0001-5183-1996
Won Suk ChoiDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0001-5874-4764
Jacob LeeDivision of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.ORCID 0000-0002-3160-1314
Joon Young SongDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.; Asian Pacific Influenza Institute (APII), Seoul, Korea.ORCID 0000-0002-0148-7194
Hee Jin CheongDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.; Asian Pacific Influenza Institute (APII), Seoul, Korea.ORCID 0000-0002-2532-1463
Woo Joo KimDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.; Asian Pacific Influenza Institute (APII), Seoul, Korea.ORCID 0000-0002-4546-3880
Korea University · KRHallym University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrevious studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. MATERIALS AND

methodsDuring the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period.

resultsA total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis (PCV13+IIV3, n=110; PPV23+IIV3, n=110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups.

conclusionPCV13+IIV3 and PPV23+IIV3 demonstrated similar immunogenicity and safety in the elderly.

Indexed as

ImmunogenicityInfluenzaPneumococcusSafetyVaccine

Identifiers

PMID28168172
PMCPMC5292355
OpenAlexW2583484015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.